Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in refractory rheumatoid arthritis.

A M Boerbooms1, M E Jeurissen, A A Westgeest

  • 1Department of Rheumatology, Academic Hospital Nijmegen, The Netherlands.

Clinical Rheumatology
|June 1, 1988
PubMed
Summary

Low-dose methotrexate effectively treats severe rheumatoid arthritis in patients unresponsive to other therapies. This pilot study shows significant symptom and inflammation reduction with manageable side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement characteristics of a new rapid anti-CCP2 test compared to the anti-CCP2 ELISA.

Scandinavian journal of rheumatology·2008
Same author

European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA?

Clinical and experimental rheumatology·2002
Same author

Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis.

Rheumatology (Oxford, England)·2001
Same author

Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis.

The American journal of pathology·2001
Same author

The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

Arthritis and rheumatism·2001
Same author

[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].

Nederlands tijdschrift voor geneeskunde·2001

Area of Science:

  • Rheumatology
  • Clinical Pharmacology

Background:

  • Severe rheumatoid arthritis often presents treatment challenges.
  • Patients refractory to conventional therapies require alternative options.

Purpose of the Study:

  • To evaluate the efficacy and safety of low-dose oral methotrexate in patients with severe rheumatoid arthritis.
  • To assess methotrexate's impact on clinical symptoms and inflammatory markers.

Main Methods:

  • Open-label, 6-month study with a 12-month follow-up.
  • Oral methotrexate administered at 2.5-5 mg three times weekly.
  • Assessed joint pain, stiffness, swelling, patient well-being, and laboratory markers.

Main Results:

  • Significant reductions in morning stiffness, joint tenderness, and swelling (p<0.01).

Related Experiment Videos

  • Improvements in visual analog scale, patient assessment, and erythrocyte sedimentation rate (p<0.001).
  • Reduced C-reactive protein and immunoglobulin levels (p<0.01); nausea and transaminase elevation observed.

    • Conclusions:

    • Weekly low-dose methotrexate is effective for short-term treatment of refractory rheumatoid arthritis.
    • Methotrexate demonstrates significant clinical and biochemical improvements.
    • Adverse events were generally mild, with two patients discontinuing treatment.